Several classes of orally administered HDAC inhibitors have been found to attenuate the progression of certain cancers and neurodegenerative diseases, including Alzheimer’s disease and Huntington’s disease (Chuang et al., 2009). The gene discussed is HDAC9; the disease is cancer.